Sains Malaysiana 48(10)(2019): 2239–2248

http://dx.doi.org/10.17576/jsm-2019-4810-20

The Value of PET-CT Scan in Determining Remission Status in Lymphoma Patients Involving the Head & Neck Region

(Penilaian Imbasan PET-CT dalam Menentukan Status Sembuh di Bahagian Kepala & Leher Pesakit Limfoma)

WAN FARIZA WAN JAMALUDIN*¹, FARA RAHIDAH HUSIN², AINI AB. AZIZ^3,4, MOHD RAZIF MOHD YUNUS⁵, MAWADDAH AZMAN⁵, KONG MIN HAN⁵, NORAIDAH MASIR⁶, MAHDIEH GHODDOOSI⁶, SEERY ZALIZA AZURA ZAIDER¹, NORMI MUSTAPHA⁷, NOR ASIAH MUHAMAD⁸ & S FADILAH ABDUL WAHID¹

¹Pusat Terapi Sel, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Federal Territory, Malaysia

²Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia

³Department of Nuclear Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Federal Territory, Malaysia

⁴Department of Radiology, National Heart Institute of Malaysia, 145, Jalan Tun Razak, Bandar Tun Razak, 50400 Kuala Lumpur, Federal Territory, Malaysia

⁵Department of Otorhinolaryngology, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Federal Territory, Malaysia

⁶Department of Pathology, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Federal Territory, Malaysia

⁷Faculty Science & Technology, Open University Malaysia, Jalan Tun Ismail, 50480 Kuala Lumpur, Federal Territory, Malaysia

⁸Non Communicable Disease Section, Ministry of Health, Complex E, Federal Government Administrative Building, 62590 Putrajaya, Federal Territory, Malaysia

Diserahkan: 24 Januari 2019/Diterima: 3 September 2019

ABSTRACT

In lymphoma, Positron Emission Tomography-Computerized Tomography (PET-CT) provides greater prognostic information than conventional imaging. However, false positivity occurred particularly in the head & neck due to predilection for infection and inflammation. We investigated the association between positive scans in the head & neck at the end of therapy with histology, and its diagnostic and prognostic values. 488 PET-CT were retrospectively assessed in 2012-2016 (40 months). Positive uptakes in the head & neck (five-point scale ≥4) were biopsied. Prevalence of positive scans was 10.9% (53/488). Two positive scans were histologically lymphomatous with mean maximum standardized uptake value (SUVmax) of 9.0±2.69. False positivity (96.2%) was histologically attributed to reactive lymphoid hyperplasia (SUVmax 9.0±3.88). Positive and negative predictive values, sensitivity and specificity were 3.8%, 100%, 100% and 89.5%, respectively. False positivity was associated with age, gender, extra-nodal involvement, Eastern Cooperative Oncology Group score (ECOG), positivity only in the head & neck and its pattern of positivity. No significant predictors were identified. Hodgkin Disease (HD) was more likely to have positivity only in the head & neck compared to Non-Hodgkin Lymphoma (NHL) (p=0.019). 106 patients with negative scans remained negative during study period, hence regarded as true negatives. Positive scans in the head & neck at post therapy yielded high false positivity and should not be routinely performed. HD has higher likelihood of scan positivity only in the head & neck than NHL. The value of PET-CT to detect true lymphomatous relapse in selected high-risk patients remained to be confirmed in future trials.

Keywords: Head & neck; lymphoma; PET-CT

ABSTRAK

Dalam limfoma, imbasan Positron Emission Tomography-Computerized Tomography (PET-CT) memberi maklumat prognosis yang lebih mendalam berbanding imbasan konvensional. Namun, keputusan positif palsu berlaku terutama di bahagian kepala & leher kerana tisu limfoid di situ sering terdedah kepada radang dan jangkitan. Kami mengkaji hubung-kait antara imbasan positif di bahagian kepala & leher dengan histologi serta nilainya dalam maklumat diagnostik dan prognostik. 488 imbasan PET-CT setelah rawatan tamat telah dikaji secara retrospektif antara 2012-2016 (40 bulan). Imbasan positif di kepala & leher (skor berskala lima ≥4) dihantar untuk biopsi. Kelaziman imbasan positif ialah 10.9% (53/488). Hanya dua imbasan positif terbukti mengandungi histologi limfoma, dengan bacaan SUVmax 9.0±2.69. Imbasan positif palsu (96.2%) mengandungi histologi limfoid hyperplasia reaktif (SUVmax 9.0±3.88). Nilai ramalan positif dan negatif, kesensitifan dan kekhususan adalah 3.8%, 100%, 100% dan 89.5%. Imbasan positif palsu dikaitkan dengan umur, jantina, penglibatan extra-nodal, ECOG, positif di kepala & leher sahaja, dan corak positif, namun tiada faktor peramal dapat dikenal pasti. Hodgkin Disease (HD) dikenal pasti sebagai peramal untuk mempunyai imbasan positif di kepala & leher sahaja berbanding Non-Hodgkin Lymphoma (NHL) (p=0.019). 106 pesakit yang mempunyai imbasan negatif kekal sembuh sepanjang tempoh kajian, maka mereka dianggap sebagai negatif tulen. Kesimpulannya, imbasan positif di kepala & leher selepas tamat rawatan menunjukkan kadar positif palsu yang tinggi dan tidak harus dijalankan secara rutin. HD lebih berkemungkinan tinggi untuk mendapat imbasan positif di kepala & leher sahaja berbanding NHL. Nilai imbasan PET-CT untuk mengesan limfoma berulang dalam kalangan pesakit berisiko tinggi harus dikaji lagi dalam penyelidikan pada masa akan datang.

Kata kunci: Kepala & leher; limfoma; PET-CT

RUJUKAN

Ancey, P.B., Contat, C. & Meylan, E. 2018. Glucose transporters in cancer: From tumor cells to the tumor microenvironment. The FEBS Journal. https://doi.org/10.1111/febs.14577.

Avivi, I., Zilberlicht, A., Dann, E.J., Leiba, R., Faibish, T., Rowe, J.M. & Bar-Shalom, R. 2013. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. American Journal of Hematology 88(5): 400-405.

Barrington, S.F. & Kluge, R. 2017. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. European Journal of Nuclear Medicine and Molecular Imaging 44(1): 97-110.

Barrington, S.F., Mikhaeel, N.G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S.P., Schwartz, L.H., Zucca, E., Fisher, R.I. & Trotman, J. 2014. Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on malignant lymphomas imaging working group. Journal of Clinical Oncology 32(27): 3048-3058.

Brink, I., Reinhardt, M.J., Hoegerle, S., Altehoefer, C., Moser, E. & Nitzsche, E.U. 2001. Increased metabolic activity in the thymus gland studied with^ 1^ 8F-FDG PET: Age dependency and frequency after chemotherapy. Journal of Nuclear Medicine 42(4): 591-595.

Cheson, B.D., Fisher, R.I., Barrington, S.F., Cavalli, F., Schwartz, L.H., Zucca, E., Lister, Alliance, Australasian Leukaemia and Lymphoma Group., Eastern Cooperative Oncology Group., European Mantle Cell Lymphoma Consortium., Italian Lymphoma Foundation., European Organisation for Research., Treatment of Cancer/Dutch Hemato-Oncology Group., Grupo Español de Médula Ósea., German High- Grade Lymphoma Study Group., German Hodgkin’s Study Group., Japanese Lymphorra Study Group., Lymphoma Study Association., NCIC Clinical Trials Group., Nordic Lymphoma Study Group., Southwest Oncology Group. & United Kingdom National Cancer Research Institute. 2014. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: The Lugano classification. Journal of Clinical Oncology 32(27): 3059-3068.

Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A. & Zucca, E. 2007. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology 25(5): 579-586.

Cohen, J.B., Behera, M., Thompson, C.A. & Flowers, C.R. 2017. Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. Blood 129(5): 561-564.

Fadilah Abdul Wahid. 2009. Fundamentals of the management of non-Hodgkin lymphoma. Medical Journal of Malaysia 64(4): 333-340.

Goldschmidt, N., Or, O., Klein, M., Savitsky, B. & Paltiel, O. 2011. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Annals of Hematology 90(2): 165-171.

Han, H.S., Escalon, M.P., Hsiao, B., Serafini, A. & Lossos, I.S. 2008. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Annals of Oncology 20(2): 309-318.

Kazama Toshiki, Silvana C Faria, Vithya Varavithya, Sith Phongkitkarun, Hisao Ito & Homer A. Macapinlac. 2005. FDG PET in the evaluation of treatment for lymphoma: Clinical usefulness and pitfalls. Radiographics 25(1): 191- 207.

Levine, J.M., Weiner, M. & Kelly, K.M. 2006. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. Journal of Pediatric Hematology/Oncology 28(11): 711-714.

Meignan, M., Hutchings, M. & Schwartz, L.H. 2015. Imaging in lymphoma: The key role of fluorodeoxyglucose-positron emission tomography. The Oncologist 20(8): 890-895.

Moskowitz, C.H. 2012. Interim PET-CT in the management of diffuse large B-cell lymphoma. ASH Education Program Book 2012(1): 397-401.

Myers, E.N. 2010. Head and neck oncology-2010, Part I. Otolaryngologia Polska 64(3): 136-146.

National Comprehensive Cancer Network (NCCN). 2018a. B-Cell Lymphomas. Accessed on 21 January 2019.

National Comprehensive Cancer Network (NCCN). 2018b. Hodgkin Lymphoma. Accessed on 21 January 2019.

Rahmouni, A., Luciani, A. & Itti, E. 2005. MRI and PET in monitoring response in lymphoma: Wednesday 5 October 2005, 08: 30-10: 00. Cancer Imaging 5: S106-S112.

Sarji, S. Ahmad. 2006. Physiological uptake in FDG PET simulating disease. Biomedical Imaging and Intervention Journal 2(4): 59. doi: 10.2349/biij.2.4.e59.

Schaefer, N.G., Taverna, C., Strobel, K., Wastl, C., Kurrer, M. & Hany, T.F. 2007. Hodgkin disease: Diagnostic value of FDG PET/CT after first-line therapy-Is biopsy of FDG-avid lesions still needed? Radiology 244(1): 257-262.

Sehn, L.H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O’Reilly, S., Spinelli, J.J. & Sutherland, J. 2005. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J. Clin. Oncol. 23(22): 5027-5033.

Sher, D.J., Mauch, P.M., Van Den Abbeele, A., LaCasce, A.S., Czerminski, J. & Ng, A.K. 2009. Prognostic significance of mid-and post-ABVD PET imaging in Hodgkin’s lymphoma: The importance of involved-field radiotherapy. Annals of Oncology 20(11): 1848-1853.

Tan, L.H.C. 2004. Lymphomas involving Waldeyer’s ring: Placement, paradigms, peculiarities, pitfalls, patterns and postulates. Annals-Academy of Medicine Singapore 33: 15-26.

Wafa Allam, Nabil Ismaili, Sanaa Elmajjaoui, Bel K Elgueddari, Mohammed Ismaili & Hassan Errihani. 2009. Primary nasopharyngeal non-Hodgkin lymphomas: A retrospective review of 26 Moroccan patients. BMC Ear, Nose and Throat Disorders 9(1): 11. https://doi.org/10.1186/1472-6815-9-11.

Zinzani, P.L., Stefoni, V., Tani, M., Fanti, S., Musuraca, G., Castellucci, P., Marchi, E., Fina, M., Ambrosini, V. & Pellegrini, C. 2009. Role of [18F] fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J. Clin. Oncol. 27(11): 1781-1787.

*Pengarang untuk surat-menyurat; email: wanfariza@ppukm.ukm.edu.my